An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Silverback Therapeutics to Participate in the H.C. Wainwright Hepatitis B Virus (HBV) Conference
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
Silverback Therapeutics, Inc. (SBTX), a clinical-stage biopharmaceutical company, will participate in the H.C. Wainwright Hepatitis B Virus Conference on October 13, 2021. CEO Laura Shawver and President Valerie Odegard will conduct a fireside chat at 10:30 a.m. ET (7:30 a.m. PT). The presentation will also be available via live webcast on Silverback’s investor relations website. Silverback utilizes its ImmunoTAC technology to develop targeted therapeutics for cancer and chronic viral infections.
Positive
None.
Negative
None.
SEATTLE--(BUSINESS WIRE)--
Silverback Therapeutics, Inc. (Nasdaq: SBTX) (“Silverback”), a clinical-stage biopharmaceutical company leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered, tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases, today announced that the Company will participate in the H.C. Wainwright Hepatitis B Virus (HBV) Conference on Wednesday, October 13, 2021.
Laura Shawver, Ph.D., Silverback’s Chief Executive Officer, and Valerie Odegard, Ph.D., Silverback’s President and Chief Scientific Officer, will participate in a fireside chat on Wednesday, October 13, 2021, at 10:30 a.m. ET (7:30 a.m. PT). The live webcast of the presentation will be available on Silverback’s investor relations website.
About Silverback Therapeutics
Silverback Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on leveraging its proprietary ImmunoTAC technology platform to develop systemically delivered and tissue targeted therapeutics for the treatment of cancer, chronic viral infections, and other serious diseases. Silverback’s platform enables the strategic pairing of proprietary payloads that modulate key disease modifying pathways with monoclonal antibodies directed at specific disease sites. Initially, Silverback is creating a new class of targeted immuno-oncology agents that direct a TLR8 agonist myeloid cell activator to the tumor microenvironment in solid tumors to promote cancer cell killing. Silverback Therapeutics is located in Seattle, Washington. To learn more, visit www.silverbacktx.com.
When is Silverback Therapeutics participating in the Hepatitis B Virus Conference?
Silverback Therapeutics will participate in the Hepatitis B Virus Conference on October 13, 2021.
Who will represent Silverback at the H.C. Wainwright Conference?
CEO Laura Shawver and President Valerie Odegard will represent Silverback at the conference.
What time is Silverback's fireside chat at the conference?
Silverback's fireside chat is scheduled for 10:30 a.m. ET on October 13, 2021.
Where can I watch the Silverback Therapeutics presentation?
The presentation will be available via live webcast on Silverback’s investor relations website.
What is Silverback Therapeutics known for?
Silverback Therapeutics is known for its proprietary ImmunoTAC technology platform aimed at developing targeted therapeutics for cancer and chronic viral infections.
